Phase 2 Start~month

Phase 2 Start: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the E

Indication
Facioscapulohumeral Muscular Dystrophy; FSHD

Other upcoming events for SRRK

Patent ExpiryPatent/Exclusivity Expiry: SPINRAZA
Patent ExpiryPatent/Exclusivity Expiry: EVRYSDI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the E — SRRK Phase 2 Start | BioSniper